HVTN 083
Status:Completed
Phase:I
Principal Investigator(s):Xia Jin, MD, PhD
Objective:To evaluate the safety and immune response of an adenovirus-based HIV-1 vaccine regimen that includes two vaccines given at different time points in HIV-uninfected adults.
last updated March 30, 2021
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Placebo, Randomized
Arms and Assigned Interventions
DescriptionrAd35 Env A vaccine at baseline and the rAd5 Env A vaccine at Month 3.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionrAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionrAd35 Env A vaccine at baseline and at Month 3.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionrAd5 Env A vaccine at baseline and at Month 3.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionrAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
Mode of DeliveryIntramuscular
ARMsExperimental
Official Code:
NCT01095224
Trial Sponsors:
NIAID
Start Date
End Date
October 31, 2010
March 30, 2016
Enrollment:180
Age range:
18 Years ↔
50 Years
Population:Cisgender Men, Cisgender Women